|1.||Takimoto, C H: 1 article (09/2001)|
|2.||Wright, J: 1 article (09/2001)|
|3.||Harold, N: 1 article (09/2001)|
|4.||Dahut, W: 1 article (09/2001)|
|5.||Liang, M: 1 article (09/2001)|
|6.||Band, R A: 1 article (09/2001)|
|7.||Cottrell, J: 1 article (09/2001)|
|8.||Shapiro, J D: 1 article (09/2001)|
|9.||Allegra, C J: 1 article (09/2001)|
|10.||Smith, J A: 1 article (09/2001)|
04/01/1997 - "9-AC lactone and total (lactone plus carboxylate) plasma concentrations were measured in 44 patients with solid tumors using a high-performance liquid chromatography (HPLC) assay. "
02/01/2001 - "The objectives of this study were to evaluate the antitumor activity of 9-AC in a panel of pediatric solid tumor xenografts and to relate the 9-AC lactone systemic exposure, defined as area under the concentration time curve (AUC), to the antitumor dose associated with tumor regression in the xenograft model. "
01/01/2001 - "The kinetics of the active derivative 9-AC lactone in cell culture media was defined, and then 9-AC cytotoxicity against human breast (MCF-7), bladder (MGH-U1), and colon (HT-29) cancer cell lines was studied. "
|4.||Head and Neck Neoplasms (Head and Neck Cancer)
|1.||Heterologous Transplantation (Xenotransplantation)